Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 3Not yet recruiting 2Unknown 1

Sponsor Class

OTHER 15NIH 2UNKNOWN 1OTHER_GOV 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Breast Neoplasms 66Neoplasms 49Stomach Neoplasms 45Colorectal Neoplasms 42Carcinoma, Non-Small-Cell Lung 37Lung Neoplasms 30Uterine Cervical Neoplasms 28Rectal Neoplasms 28Carcinoma, Hepatocellular 25Prostatic Neoplasms 24Recurrence 21Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Ovarian Neoplasms 18Neoplasm Metastasis 16Colonic Neoplasms 16Esophageal Neoplasms 15Urinary Bladder Neoplasms 14Thyroid Neoplasms 14Pancreatic Neoplasms 14Nasopharyngeal Carcinoma 14Leukemia, Myeloid, Acute 13Head and Neck Neoplasms 13Small Cell Lung Carcinoma 11Papillomavirus Infections 11Multiple Myeloma 11Motor Activity 11Melanoma 11Lymphoma 11Sarcoma 10Lymphoma, Non-Hodgkin 10

Interventions

aumolertinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × OTHER_GOV × Meningeal Carcinomatosis × Clear all
NCT04778800 2021-08-31

A Dose Exploration Study of Almonertinib for EGFRm NSCLC Patients With Brain/Leptomeningeal Metastasis (ARTISTRY)

Henan Cancer Hospital

Phase NA Unknown
60 enrolled
CNS

Brain Neoplasms, Meningeal Carcinomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡